US2022127637A1PendingUtilityA1
Transcriptional regulatory element and its use in enhancing the expression of heterologous protein
Assignee: WUXI BIOLOGICS IRELAND LTDPriority: Aug 14, 2018Filed: Jan 10, 2022Published: Apr 28, 2022
Est. expiryAug 14, 2038(~12.1 yrs left)· nominal 20-yr term from priority
Inventors:Zheng ZhangXiaolu LiYuchen ZhangYarong LiHuifang DongJill CaiWeichang ZhouChris ChenLili MuChuanlong Tang
C07K 16/2818C07K 16/241C07K 2317/14C12N 15/67A61P 37/00C12N 2503/00C12N 2830/30C07K 2317/21C12N 2840/105C07K 14/43595C12N 15/85C12N 2830/85C12N 15/64C07K 2317/76A61P 35/00C12N 15/113C12N 5/0682C07K 16/2827G01N 33/68A61K 2039/505
56
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Provided is a polynucleotide the polynucleotide can be used as a WXRE transcriptional regulatory element used to increase the protein expression level of a protein expression system. A protein expression vector or a protein expression systems comprising the above-mentioned WXRE transcriptional regulatory element as well as the use thereof are also provided. The use of the WXRE transcriptional regulatory element can increase the expression level of a heterologous protein greatly with its biological activity unchanged.
Claims
exact text as granted — not AI-modified1 .- 20 . (canceled)
21 . A vector comprising a heterologous nucleotide sequence and a nucleotide sequence selected from the group consisting of (i) to (ii):
(i) a sequence having at least 90% sequence identity with any of SEQ ID NOs: 3-9; and (ii) a sequence having at least 90% sequence identity with a reverse complementary sequence of any of SEQ ID NOs: 3-9.
22 . The vector of claim 21 , further comprising a nucleotide sequence selected from the group consisting of (iii) to (iv):
(iii) a sequence having at least 80% sequence identity with SEQ ID NO: 13; and (iv) a sequence having at least 80% sequence identity with a reverse complementary sequence of SEQ ID NO: 13
23 . The vector of claim 21 , further comprising a CMV promoter.
24 . The vector of claim 23 , wherein the CMV promoter comprises a nucleotide sequence having at least 80% sequence identity with SEQ ID NO: 16.
25 . The vector of claim 23 , wherein the CMV promoter comprises a nucleotide sequence that is identical to SEQ ID NO: 16.
26 . The vector of claim 22 , wherein the nucleotide sequence selected from the group consisting of (iii) to (iv) has at least 90% sequence identity with SEQ ID NO: 13.
27 . The vector of claim 22 , wherein the nucleotide sequence selected from the group consisting of (iii) to (iv) is identical to SEQ ID NO: 13.
28 . The vector of claim 21 , wherein the nucleotide sequence selected from the group consisting of (i) to (ii) has at least 90% sequence identity to SEQ ID NO: 3.
29 . The vector of claim 21 , wherein the nucleotide sequence selected from the group consisting of (i) to (ii) has at least 90% sequence identity to SEQ ID NO: 4.
30 . The vector of claim 21 , wherein the nucleotide sequence selected from the group consisting of (i) to (ii) has at least 90% sequence identity to SEQ ID NO: 5.
31 . The vector of claim 21 , wherein the nucleotide sequence selected from the group consisting of (i) to (ii) has at least 90% sequence identity to SEQ ID NO: 6.
32 . The vector of claim 21 , wherein the nucleotide sequence selected from the group consisting of (i) to (ii) has at least 90% sequence identity to SEQ ID NO: 7.
33 . The vector of claim 21 , wherein the nucleotide sequence selected from the group consisting of (i) to (ii) has at least 90% sequence identity to SEQ ID NO: 8.
34 . The vector of claim 21 , wherein the nucleotide sequence selected from the group consisting of (i) to (ii) has at least 90% sequence identity to SEQ ID NO: 9.
35 . The vector of claim 21 , wherein the heterologous nucleotide sequence encodes one or more proteins, wherein the one or more proteins are selected from a group consisting of an antibody, a fusion protein, an enzyme, a soluble protein, a membrane protein, a structural protein, a ribosome protein, a zymogen, a cell surface receptor protein, a transcriptional regulatory protein, a translational regulatory protein, a chromatin protein, a hormone, a cell cycle regulatory protein, a G protein, a neuroactive peptide, an immunomodulatory protein, a blood component protein, an ion gate protein, a heat shock protein, a dihydrofolate reductase, an antibiotic resistance protein, and a fragment thereof.
36 . A host cell comprising the vector of claim 21 .
37 . The host cell of claim 36 , wherein the host cell is a Chinese hamster ovary (CHO) cell.
38 . A method of preparing a host cell that stably expresses a protein, the method comprising: inserting into a host cell the vector of claim 21 .
39 . The method of claim 38 , wherein the host cell is a Chinese hamster ovary (CHO) cell.
40 . A method of preparing a protein, comprising: culturing the host cell of claim 36 under conditions for production of the protein.Join the waitlist — get patent alerts
Track US2022127637A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.